Hyperlactatemia During and After Tumorcraniotomy

Elevated Serum-lactate in Patients With Brain Tumor During and After Elective Craniotomy: an Observational Clinical Study of Postoperative Patient Outcome.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04410315

Enrollment

450

Registered

2020-06-01

Start date

2020-07-28

Completion date

2022-02-18

Last updated

2022-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Brain Tumor, Hyperlactatemia, Surgery

Brief summary

This study aims to investigate the association between hyperlactatemia and neurological disability, length-of-stay and mortality in patients who undergo tumorcraniotomy. The risk factors that induce lactat accumulation will also be explored.

Detailed description

Hyperlactatemia is a frequent occurrence in brain tumor surgery. The existing studies, however, are all retrospective, reporting varying effects on clinical outcome. One study reported new neurological deficitis, some found an association with extended hospital stay, while others found no association with outcome. It is therefore important to conduct a prospective study of hyperlactatemia in this patientgroup. Participants in this study will follow the standard treatment protocol for tumorcraniotomy, aside from 2-3 additional, perioperative blodgas analyses and 2 standardized measurements of neurological disability.

Interventions

OTHERSerum-lactate < 2,2 mmol/L

Bloodgas analysis every hour from start surgery until recovery ward discharge

OTHERSerum-lactate >/= 2,2 mmol/L

Bloodgas analysis every hour from start surgery until recovery ward discharge

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>/= 18 years * Must undergo elective tumor craniotomy * Understand oral and written Danish

Exclusion criteria

* Adults with incapacity * Stereotactic biopsy * Lack of informed and signed consent to participate in study

Design outcomes

Primary

Measure	Time frame	Description
Neurological disability	Change from baseline mRS at 30 days after surgery	Modified Rankin Scale (Scoring 0-6, high scores meaning worse outcome)

Secondary

Measure	Time frame	Description
Length of hospital stay	1 year	In days from admission to discharge.
Mortality	After 30 days, 6 months and 5 years	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026